Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma

“Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in Chicago…”

Combining an Immune Checkpoint Antibody with an Anti-Angiogenesis Inhibitor

A small phase I study combining the immune checkpoint antibody ipilimumab with the angiogenesis inhibitor antibody bevacizumab showed promising results in advanced melanoma patients in 2011. Now, researchers are continuing to study the combination of immunotherapy and anti-angiogenic agents to understand which patients could best benefit from such a combination. Continue reading…